




TEIKOKU PHARMA USA, INC.

We Focus on Improving the Quality of Life.





TEIKOKU PHARMA USA, INC.

With its origins dating back to 1848, Teikoku Pharma USA, a wholly-owned subsidiary of Teikoku Seiyaku Co., is one of the oldest pharmaceutical companies worldwide concentrating on transdermal drug delivery and pain management.

In our continuous effort to guarantee improved quality of life, we are focusing on expanding our product line of patches and ointments used in hospitals, clinics, and homes everywhere. Our key technologies have always been and will continue to be on transdermal preparations in the form of poultices and plasters.

We back our commitment of genuinely caring for people by strict adherence to the highest standards in research and development of Drug Delivery Systems (DDS) capable of providing precise and predictable drug release rates with greater efficacy and minimal side-effects.

We will not stray from our pledge to meet and even exceed the Good Manufacture Practice (GMP) guidelines throughout the manufacturing cycle. Teikoku Pharma USA continues to expand its capabilities, with the latest effort being the startup of the only FDA-approved hydrogel patch GMP manufacturing facility in the world.

Products

Through our globalized-approach to international cooperation, exchange of information, and R&D, Teikoku Pharma USA is a leader in establishing partnerships for the purpose of co-developing new and inventive private-branded formulations to fit your specific market requirements.

Whether you're looking for a new formulation or a well established product, we have the expertise to deliver exactly what you need. We can offer you an existing line of more than 200 medicated patches, ointments, jellies, unit solutions, and capsules, as well as a line of cosmetic sheet products to choose from.

Our parent company, Teikoku Seiyaku Co., was the first to develop analgesic plasters. We offer over a century of experience in developing plasters that bring quicker relief and sustained pain management as analgesic and anti-inflammatory medications are absorbed directly through the skin. We continue our long and dedicated history of pioneering the discovery of new, fast acting, pain-relieving medicated patch and plaster formulations—producing more than 1.2 billion patches every year.

Healthcare institutions in over 40 countries use more than 80% of our products to aid millions of people find immediate relief, enabling them to more effectively manage pain.



For more information about products, services, or private label opportunities, contact us at: info@teikokuusa.com.

Technology

Over the more than 150 years that we have been producing quality pharmaceutical products for both the domestic and foreign markets, Teikoku Pharma USA, as a subsidiary of Teikoku Seiyaku, has diligently strived to incorporate the most advanced, leading-edge technology to support our Research and Development.

We produce over 200 medicated patch and plaster products for clinical and household use, as well as a line of cosmetics, in a pristine production environment to guarantee antiseptic conditions exceeding those required by the Pharmaceutical Affairs Law and Good Manufacturing Practice (GMP) guidelines. For every drug and its unique properties, we develop a patch with matching properties and adhesive, and prolonging the therapeutic benefits.

By linking our Research and Development labs with our state-of-the-art production plants through integrated technologies, we can effortlessly transform the first glimmer of an idea into a tangible product—in months rather than years—that will benefit millions of people around the world.

Every Teikoku Pharma USA product is rigorously inspected every step of the way, from development to manufacturing and shipment. Through thought leadership, international collaborations with research organizations, and insightful exploration into the newest technologies, we lead the way in discovering futuristic opportunities within the pharmaceutical industry.

*Teikoku Pharma USA
combines its more than
150 years of experience
in developing transdermal
and topical drug delivery
systems, along with its
adhesive expertise to meet
your market requirements.*

You can be a part of the Teikoku Pharma USA family through our, private-labeling or other collaborative programs. Be a part of 150 years of bringing health and beauty products that enhance the health and well being of our customers all over the world.

History

With a Master of Economics degree from the University of California (UCLA), Shosaku Murayama, the newly appointed president of the Teikoku Group, has made it his mission to globalize the company, adding a new page to its long history dating back to its founding in 1848. Other company milestones include:

- 1918 The company was re-organized under the name, Teikoku Seiyaku Co. Ltd. with capital of over 1-million yen.
- 1938 The company produces Horxis, the first analgesic plaster product.
- 1942 Teikoku Seiyaku Beijing established.
- 1953 Company begins manufacturing raw and intermediary materials for pharmaceutical products from its new plant in Osaka, Japan.
- 1957 Osaka plant is spun off as Fuso Chemical Industry Co., Ltd. to produce industrial chemicals.
- 1974 The first medicated plaster product is approved for clinical use, ultimately becoming the company's main product line.
- 1988 Production begins on Catlep (Indomethacin), the first approved hydrogel patch.
- 1992 Teikoku Medix Co., Ltd. spun off as an independent sales company.
- 1993 Seltouch (Felbinac) patch for medical use receives approval and company begins production.
- 1995 Teikoku Pharmacare Co., Ltd. spun off to produce OTC drugs, and Teikoku Seiyaku joins the Japan Pharmaceutical Manufacturers' Association.
- 1997 Headquarters for U.S. subsidiary, Teikoku Pharma USA, established in San Jose, California.
- 1999 Through a joint venture with Endo Pharmaceuticals, Lidoderm receives FDA approval to treat pain associated with postherpetic neuralgia (PHN), a complication of shingles (herpes zoster) that affects more than 200,000 Americans every year.
- 2000 Dovonex ointment, used to treat psoriasis, receives approval in Japan and goes on sale. Teikoku Pharma USA expands and relocates to Campbell, California facility.
- 2001 Teikoku Pharma UK, Ltd. established in London, UK.
- 2002 Shosaku Murayama assumes position as president of Teikoku Group.





TEIKOKU PHARMA USA, INC.

745-D Camden Avenue
Campbell, California 95008-4146
USA

Main: (408) 341-0130
Fax: (408) 374-0181
Email: info@TeikokuUSA.com
Web site: www.teikokuusa.com

Headquarters

Teikoku Seiyaku Co., Ltd.
567 Sanbonmatsu
Higashikagawa, Kagawa 769-2695
Main: +81-879-25-2221
Fax: +81-879-23-1555
Web site: www.teikoku.co.jp



Bringing health and beauty to people around the world.